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Abstract
Multiple sclerosis (MS) is an autoimmune disease where T-cells activated against myelin antigens are involved in myelin
destruction. Yet, healthy subjects also harbor T-cells responsive to myelin antigens, suggesting that MS patient-derived
autoimmune T-cells might bear functional differences from T-cells derived from healthy individuals. We addressed this issue
by analyzing gene expression patterns of myelin oligodendrocytic glycoprotein (MOG) responsive T-cell lines generated from
MS patients and healthy subjects. We identiﬁed 150 transcripts that were differentially expressed between MS patients and
healthy controls. The most informative 43 genes exhibited .1.5-fold change in expression level. Eighteen genes were up-
regulated including BCL2, lifeguard, IGFBP3 and VEGF. Twenty ﬁve genes were down-regulated, including apoptotic
activators like TNF and heat shock protein genes. This gene expression pattern was unique to MOG speciﬁc T-cell lines and
was not expressed in T-cell lines reactive to tetanus toxin (TTX). Our results indicate that activation in MS that promotes
T-cell survival and expansion, has its own state and that the unique gene expression pattern that characterize autoreactive T-
cells in MS represent a constellation of factors in which the chronicity, timing and accumulation of damage make the
difference between health and disease.
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Introduction
Multiple sclerosis (MS) is a chronic inﬂammatory
demyelinating disease of the central nervous system
and the most common cause of disability in young
adults. The etiology of MS involves autoimmune
mechanisms within the background of genetic
susceptibility (Compston and Sawcer 2002). Myelin
sheath-derived antigenic epitopes involving predomi-
nantly myelin basic protein (MBP), myelin
oligodendrocyte glycoprotein (MOG) and the proteo-
lipid protein (PLP) are targets for the autoimmune
T-cell activation in MS patients. These autoreactive
T-cells cause inﬂammatory reaction leading to myelin
damage and axonal loss (Stinissen et al. 1998, Gran
and Rostami 2001). The autoreactive T-cells can be
generated and propagated as speciﬁc T-cell lines
from MS patients and are being used following
attenuation to vaccinate MS patients against the
disease (Zhang et al. 1993, Achiron et al. 2004). The
frequency of autoimmune T-cells is inﬂuenced by
immune regulatory mechanisms involving cytokine
stimulation and apoptotic deletion (Pender 1998).
It has been reported that activated T-cell lines
responsive to MBP, MOG and other myelin epitopes
can be also propagated from peripheral blood
mononuclear cells of healthy subjects (Ota et al.
1990). This fact led us to examine whether
autoreactive T-cell lines derived from MS patients
bear functional differences relative to T-cell lines
obtained from healthy subjects, in order to evaluate
whether these differences bear implications for the
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microarray analysis (Duggan et al. 1999) to determine
gene expression of MOG stimulated T-cell lines
derived from MS patients in comparison to healthy
controls. We chose to study T-cells responsive to
MOG as this myelin epitope is expressed preferentially
on the outermost surface of the myelin sheath, is
highly immunogenic and was reported to induce
severe experimental autoimmune encephalomyelitis
(EAE) in both rodents and primates (Zhong et al.
2000), as well as to serve a major target for
autoimmune T-cells in MS patients (Weissert et al.
2002).
Materials and methods
Subjects
Four female patients with deﬁnite MS and a relapsing-
remitting course (mean age 38 þ 4.2 years, mean
disease duration 9.3 þ 3.3 years) and three age- and
sex-matched healthy subjects were included in the
study. None of the patients received immunomodu-
latory drugs or steroid treatment for at least 3 months
prior to blood drawn. The study was approved by the
institutional review board and the Israel Ministry of
Health. Written informed consent was obtained from
all participants.
Generation of MOG-reactive T-cell lines
Peripheral blood mononuclear cells (PBMC) were
separated on ﬁcoll-hypaque and plated in 96-well U-
bottom microplates in the presence of MOG peptide
(aa residues 34–56, 15mg/ml, Chiron) as previously
described (Zhang et al. 1993). Tetanus toxin (TTX)
peptide (aa 176–195, 15mg/ml, Hy-labs, Israel) was
used as a non-encephalitogenic control antigen.
Selection of wells for expansion of lines was performed
by
3H-thymidine incorporation into subdivided
primary cultures propagated with the peptide antigens
for 7 days and yielding a stimulation index .3 relative
to control cells grown without the peptide. The wells
were examined for IFN-g and IL-10 production by
RT-PCR. Wells positive for IFN-g and low or negative
for IL-10 were selected (Th1 cells). These cells were
subcultured on freshly obtained antigen presenting
cells (irradiated PBMC) and antigen reactive T-cell
lines were generated following expansion with IL-2,
50U/ml (Boehringer Mannheim, Germany). Cells for
analysis from both MS patients and control donors
were harvested for experiments 14–21 days after line
selection and expansion over IL-2 at the peak of the
logarithmic growth phase. T-cell lines were examined
for CD4/CD8 ratio and those with CD4 content
.60% were used for gene microarray analyses.
mRNA preparation
Total RNA was isolated from MOG stimulated T-cell
lines (2 £ 10
7cells) by ice-cold TRIZOL Reagent
(Gibco BRL). Poly-A mRNA was isolated with mini-
kit (Oligotex, Qiagen) and used as a template for
double stranded cDNA synthesis oligo (dT)-24
primers containing a T7 RNA polymerase promoter
site added to the 30- end (Genset). After phenol/
chloroform extraction cDNA was used as a template
for in-vitro transcription (Ambion T7 Megascript
system) with biotin labeled nucleotides (Enzo Diagno-
stics). Labeled cRNA was fragmented, quantiﬁed by
spectrophotometer, and hybridized.
Microarray gene analysis
Each Genechip (U95Av2, 12,000 genes) was hybri-
dized with 10mg/200ml hybridization mix, stained
and scanned (Hewlett Packard, GeneArray-TM
scanner G2500A) according to manufacturer protocol
(Affymetrix Inc, Santa Clara, CA). MAS5 software
(Affymetrix Inc.) was used to analyze the scanned
arrays. All data were normalized by dChip software.
Probes that did not have an expression value of 100 in
at least one of the arrays were ﬁltered.
Data analysis
The analysis was performed according to the
analytical approach as previously described (Lovett-
Racke et al. 1998, Ben-Dor et al. 2000, Ria et al.
2001). Fold ratios were calculated for each gene of the
samples against the geometric mean of matched
controls. To determine the most informative genes
threshold number of misclassiﬁcations (TNoM) score
was applied (Rechsteiner et al. 2000). This score
counts the number of classiﬁcation errors that occur
between compared groups for each gene of the
dataset. The best threshold (TNoM ¼ 0) implies
that no errors have been counted and the distinction
between the two groups in relation to the expression
level of a speciﬁc gene is maximal. To select a group of
genes with strongly differential expression, we also
computed t-test p-value (comparing expression levels
of genes from MS patients vs. healthy controls). Genes
with TNoM ¼ 0, fold-change .1.5 (either up or
down regulated) and corresponding t-test p value
,0.05, were designated as most informative.
Conﬁrmation of microarray gene expression
Real-Time RT-PCR analysis was preformed for three
most informative genes using the QuantiTect SYBER
Green PCR kit (QIAGEN) and speciﬁc primers for
IGF-BP3 (50- AGAATATGGTCCCTGCCGTAGA-
30,5 0- TTCAGGTGATTCAGTGTGTCTTCC-30),
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CACATCTGCAAGTACGTTCGTTTA-30)a n d
BLVRA (50- ACCTCAGTCCCACGACAGT-
TATG-30,5 0—AGGAAAGCCGAGGTGCAG-30).
b-Actin (50- CCTGGCACCCAGCACAAT-30,5 0-
GCCGATCCACACGGAGTACT-30) was used as a
control. Samples were run in triplicates and average
fold change calculated.
Results
Gene expression patterns obtained from MOG
reactive T-cell lines from MS patients disclosed 150
differentially expressed transcripts with TNoM ¼ 0,
as compared to healthy subjects. A pie-chart diagram
showing the functional groups of these genes is
presented in Figure 1.
Hierarchical clustering of the 150 differentially
expressed genes between MS patients and healthy
controls is presented in Figure 2A. We further
identiﬁed and clustered 43 most informative genes,
18 up-regulated and 25 down-regulated genes
(Figure 2B).
Analysis of the known biological function of these
genes demonstrated an apparently diverse portfolio of
activities, Table I. We identiﬁed genes coding for
proteins involved in the regulation and execution of
apoptosis, growth factors, mediators of signal trans-
duction pathways, molecules that participate in
inﬂammation and also genes encoding heat shock
proteins, transcription factors and components of
different biochemical pathways. More speciﬁcally,
genes that were up-regulated in the MS patients-
derived T-cell lines include growth factors such as
vascular endothelial growth factor (VEGF), insulin-
like growth factor binding protein 3 (IGF-BP3),
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Figure 1. Pie-chart diagram showing the functional groups of the 150 differentially expressed gene transcripts.
Figure 2. Infogram of gene expression levels of MOG stimulated
T-cell lines from MSpatients and healthy controls. (A) One hundred
and ﬁfty differentially expressed genes (TNoM ¼ 0, p , 0.05). (B)
Forty three most informative genes with TNoM ¼ 0, fold change
.1.5 and p , 0.05. Each row represents a gene and each column
refers to a T-cell line from a different subject. Genes with increased
expression (relative to average of control samples) are depicted in
yellow, and genes with decreased expression are depicted in blue.
Unique MS T-cell gene expression 205Table I. Functional characteristic of the most informative genes differentially expressed in MOG activated T-Cells between MS patients and
healthy subjects.
Identiﬁer Symbol Name Function Fold Change P value t-test
Up regulated
M35878 IGFBP3 Insulin-like growth factor binding
protein 3
Modulates IGF activity 5.8 0.03
AB002318 KIAA0320 KIAA0320 protein 2.4 0.05
AF024710 VEGF Vascular endothelial growth factor Endothelial cell proliferation 2.3 0.02
AA628946 KHSRP KH-type splicing regulatory protein mRNA processing 2.2 0.01
L42374 PPP2R5B Protein phosphatase 2, regulatory
subunit B
Protein phosphatase 2.1 0.05
U54644 TUB Tubby (mouse) homolog May be a transcription factor 1.8 0.01
AB023167 KIAA0950 Lifeguard (LFG) Apoptosis 1.8 0.006
X62654 CD63 CD63 antigen
(melanoma 1 antigen)
Growth regulation 1.8 0.03
H98552 cDNA DKFZp586I0523 1.8 0.01
AL050395 MOF Member of MYSTacetyl
transferases
Histone acetyl transferases 1.7 0.03
L27213 SLC4A3 Solute carrier family 4,
anion exchange 3
Inorganic anion exchanger 1.7 0.01
AF014837 M6A Putative methyltransferase Transcription factor 1.6 0.05
AB014537 KIAA0637 KIAA0637 gene product Apoptosis 1.5 0.003
D13969 ZNF144 Zinc ﬁnger protein 144
(Mel-18)
DNA-Binding protein 1.5 0.04
AJ012590 H6PD Hexose-6-phosphate dehydrogenase Oxidoreductase 1.5 0.04
M13995 BCL2 B-cell CLL/lymphoma 2 Apoptosis 1.5 0.03
AI760801 Chromosome 19, cosmid R31180 1.5 0.009
AI660963 MAP3K12 Mitogen-activated protein 3
kinase 12
Transferase Cytoplasmic 1.5 0.02
Down regulated
D45248 PSME2 Proteasome activator subunit 2
(PA28 b)
Protein degradation 21.5 0.04
W28612 ESTs 21.5 0.02
Z46389 VASP Vasodilator-stimulated phosphoprotein Signal transduction 21.6 0.02
AA152202 FLJ14639 Hypothetical protein FLJ14639 21.6 0.02
AF080561 RBM14 RNA binding motif protein 14 RNA binding protein 21.7 0.03
D50922 KIAA0132 Kelch-like ECH-associated protein 1 ECH-associated protein 1 21.7 0.03
AF025441 OIP5 Opa-interacting protein 5 21.8 0.04
AF080227 EED Embryonic ectoderm development Transcriptional repressor 21.8 0.04
D87957 RQCD1 Required for cell differentiation Sex differentiation 21.9 0.03
X61498 NFKB2 Nuclear factor of kappa
light polypeptide Bcells
Expression of inﬂammatory genes 21.9 0.05
X52425 IL4R Interleukin 4 receptor Receptor signalling protein 22 0.04
L08069 DNAJA1 DnaJ (Hsp40) homolog, subfamily A,
member 1
Protein folding and transport 22 0.04
AF071504 STX11 Syntaxin 11 Protein transport 22.1 0.03
M11717 HSPA1A Heat shock 70kDa protein 1A Heat shock response 22.2 0.03
M59830 HSPA1B Heat shock 70kD protein 1B Heat shock response 22.2 0.03
M16441 TNF Human tumor necrosis factor Inﬂamatory response 22.3 0.05
D89077 SLA Src-like-adapter 22.4 0.05
U77949 CDC6 Cell division cycle 6,
S. cerevisiae homolog
DNA replication checkpoint 22.5 0.02
D38549 KIAA0068 KIAA0068 protein 22.5 0.01
L23959 TFDP1 Transcription factor Dp-1 Cycle progression G1 to
S-phase
22.5 0.01
L78833 BRCA1 Breast cancer susceptibility gene 22.7 0.04
M63193 ECGF1 Endothelial cell growth factor 1 Stimulates angiogenesis 22.8 0.01
AF035625 STK11 Serine/threonine kinase 11 Peutz–Jeghers syndrome 22.9 0.04
J04130 SCYA4 Small inducible cytokine A4 Cell-to-cell signalling 22.9 0.05
X93086 BLVRA Biliverdin reductase A Biliverdin reductase 24 0.03
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as a growth regulator. Additionally anti-apoptotic
genes such as B-cell CCL/Lymphoma 2 (BCL2)
which blocks apoptosis by interfering with activation
of caspases, and the lifeguard gene (LFG)—an anti-
apoptotic component involved in inhibition of
induction of apoptosis downstream to the activating
signal generated by CD95/Fas receptor interaction
with its ligand, and the transcript for MAP activated
kinase were recognized. Down-regulated genes
included the proteasome activator subunit 2 involved
in the presentation of endogenous antigens by MHC
class I molecules and required for efﬁcient antigenic
epitope processing (Chen et al. 2001), the 70kDa heat
shock proteins 1A and B (HSP-A1A, HSP-A1B),
endothelial cell growth factor 1 (ECGF1), inﬂamma-
tory cytokines such as small inducible cytokine A4
(SCYA4) which is involved in cell-to-cell signaling,
tumor necrosis factor (TNF), interleukin-4 receptor
(IL-4R) and nuclear factor of kappa light polypeptide
gene enhancer B-cells (NF-KB2) which binds to the
kappa-B consensus sequence located in the enhancer
region of genes involved in immune response (Zettl
et al. 1998). Real time RT-PCR of three of the most
informative genes conﬁrmed the microarray ﬁndings
with high correlation between methods, Table II.
M O Gr e s p o n s i v eT - c e l ll i n eg e n ee x p r e s s i o n
signature was evaluated for speciﬁcity by comparison
with T-cell lines stimulated by TTX as a non-
encephalitogenic antigen. This comparison disclosed
that only six of the 150 MOG stimulated differentially
expressed genes (CLPTM1, VASP, PDAP1, NFKB2,
SLA and BCL2), were common with the expression
pattern of TTX stimulated lines.
Discussion
In the present study, we demonstrated that MOG
responsive T-cell lines derived from patients with MS
have inherent gene transcriptional ﬁngerprint. This
transcriptional ﬁngerprint differs from that observed
in MOG activated T-cell lines generated in healthy
subjects, although both responded to the same myelin
antigen. Moreover, this gene expression pattern was
found to be unique in MS as it was conﬁned to MOG
speciﬁc T-cell lines and not to T-cell lines reactive with
a non-encephalitogenic TTX antigen. This suggests
that the MOG stimulated expression signature in MS
is indeed speciﬁc and relates to the encephalitogenic
antigen.
The differentiating gene transcripts within the
signature indicate a functional platform of activities
that may be associated with disease pathogenesis.
Up-regulated genes include anti-apoptotic genes
such as BCL2, LFG and MAP3K12. The BCL2
gene product is an important member of the anti-
apoptotic proteins. High numbers of BCL2 positive
T lymphocytes were found in demyelinating and
remyelinating brain lesions from MS patients (Zettl
et al. 1998). Likewise, an increased frequency of
MBP-reactive T-cells in MS patients relative to
healthy individuals was detected when an antibody
to Fas-ligand was used to block apoptosis (Zang
et al. 1999). LFG is known to inhibit T-cell death
mediated by the Fas receptor (CD95) through a
unique mechanism that down regulates apoptotic
signals from Fas (Somia et al. 1999). Loss of
Fas/Fas ligand activities was reported in human
autoimmune lymphoproliferative syndrome (Van
den Berg et al. 2002), and in lymphoproliferative
lupus-like syndrome in mice (Watanabe et al.
1992). The MAP3K12 gene is associated with
programmed cell death and was reported to catalyze
the phosphorylation of BAD, a member of the
BCL2 protein family which stimulates BCL2
dependent anti-apoptotic pathways (Yang et al.
1995, Bonni et al. 1999). Another aspect of failure
to induce apoptosis in the MS-derived T-cell lines is
the signiﬁcant down-regulation of the TNF pro-
apoptotic gene. The inadequate apoptosis present in
MS autoreactive T-cell lines could lead to insufﬁ-
cient deletion of autoimmune activated T-cell clones
and increase susceptibility to autoimmunity. TNF is
also known to stimulate MHC class I presentation
in addition to induction of apoptosis. Our ﬁnding of
down-regulation of MHC class I presentation
include the PA28b involved in the presentation of
endogenous antigens and required for efﬁcient
antigenic epitope processing. Accordingly, we
suggest that a weaker antigenic MHC class I
presenting capability might distinguish MS-patient
derived T-cell lines from their healthy counterparts.
It is conceivable that a lower expression of MHC
class-I on CD4 autoimmune T-cells might enable
them to escape regulation by CD8 cells that
recognize autoimmune idiotypes (Zang et al.
2000). We also found higher expression of
IGFBP3 and VEGF in MOG responsive T- cell
lines derived from MS patients. IGFBP3 has
previously been reported to be expressed on
human stimulated and unstimulated lymphocytes
(Kooijman et al. 1995). In murine EAE, IGF-
1/IGFBP3 treatment resulted in more severe disease
Table II. Quantitative real time RT-PCR analyses for three most
informative genes from MOG responsive T-cell lines derived from
MS patients relative to healthy subjects.
Average
fold
change RT PCR
Gene
expression
Correlation
coefﬁcient
IGF-BP3 6.261 5.8 0.96
VEGF 2.3 2.3 1.0
BLVRA 0.704 0.55 0.72
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T-cells (Lovett-Racke et al. 1998).
Our ﬁndings are in agreement with these
observations, as well as with ﬁndings by others
(Lock et al. 2002) that reported increased
expression of IGFBP3 in acute brain lesions of
MS patients compared to silent MS lesions. In
addition to increased survival potential, our ﬁndings
suggest that autoreactive T-cells in MS also have an
expansion advantage compared with T-cells from
healthy individuals. Furthermore, migration of
autoimmune T-cells into the brain would be
expected to be assisted by over-expression of
VEGF. VEGF enhances vascular permeability and
may facilitate migration of lymphocytes into the
brain and induction of autoreactive inﬂammatory
response. Taken together the combined effects of
down-regulation of apoptosis associated genes, up
regulation of antiapoptotic genes, increased expan-
sion capability of autoreactive T-cells and enhanced
ability to penetrate the brain may lead to
perpetuated pathologic cellular proliferation and
tissue destruction within the central nervous system,
along with increased resistance to regulation. These
speciﬁc gene transcripts can deﬁne some of the
requirements for an individual to develop MS. It is
of noteworthy that despite activation in-vitro with
the same MOG epitope, MOG reactive T- cell lines
from healthy subjects did not attain the gene
expression proﬁle that characterized the MS
patient-derived cells. Thus, these ﬁndings support
the concept that not all autoimmune T-cells are
equal; autoimmune T-cells from MS patients follow
a unique pattern of T-cell activation that appears to
be more resilient to apoptosis and can support long
term survival. Although, T-cell lines derived from
MS patients and healthy donors responded to the
same autoantigen, the gene expression imprints that
are unique to each group were preserved. The
nature of the stimuli that generate aberrant
autoimmune T-cell gene expression has yet to be
identiﬁed in order to determine whether their
formation is merely the result of the chronic
immune stimulation driven by other factors
in MS, or whether such T-cells function are
the primary drivers of the pathogenic MS process
(Ria et al. 2001). On the other hand, the difference
we demonstrated between autoreactive T-cells in
patients and healthy subjects suggests that though
both are activated and against the same myelin
antigen their state is different, and the change in
state is of importance. This transformation between
autoimmune reactivity and autoimmune disease and
the characterization of such driver autoreactive
T-cells dictating the state of immunity–autoimmu-
nity, may contribute to understanding autoimmune
diseases and possibly contribute to the designation
of effective treatments in MS.
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